{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T20:54:26Z","timestamp":1792011266971,"version":"4.4.0"},"reference-count":192,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,2,29]],"date-time":"2020-02-29T00:00:00Z","timestamp":1582934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Somatostatin analogs are an invaluable therapeutic option in the diagnosis and treatment of somatotropinomas, thyrotropinomas, and functioning and non-functioning gastroenteropancreatic neuroendocrine tumors. They should also be considered an effective and safe therapeutic alternative to corticotropinomas, gonadotropinomas, and prolactinomas resistant to dopamine agonists. Somatostatin analogs have also shown to be useful in the treatment of other endocrine diseases (congenital hyperinsulinism, Graves\u2019 orbitopathy, diabetic retinopathy, diabetic macular edema), non-endocrine tumors (breast, colon, prostate, lung, and hepatocellular), and digestive diseases (chronic refractory diarrhea, hepatorenal polycystosis, gastrointestinal hemorrhage, dumping syndrome, and intestinal fistula).<\/jats:p>","DOI":"10.3390\/ijms21051682","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T03:13:28Z","timestamp":1583205208000},"page":"1682","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":235,"title":["Somatostatin Analogs in Clinical Practice: A Review"],"prefix":"10.3390","volume":"21","author":[{"given":"Mariana","family":"Gomes-Porras","sequence":"first","affiliation":[{"name":"Department of Endocrinology, \u201cLa Paz\u201d University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-484X","authenticated-orcid":false,"given":"Jersy","family":"C\u00e1rdenas-Salas","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, \u201cFundaci\u00f3n Jim\u00e9nez-Diaz\u201d University Hospital. Av. de los Reyes Cat\u00f3licos, 2, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"\u00c1lvarez-Escol\u00e1","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, \u201cLa Paz\u201d University Hospital. Paseo de la Castellana, 261, 28046 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1126\/science.179.4068.77","article-title":"Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone","volume":"179","author":"Brazeau","year":"1973","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International union of basic and clinical pharmacology. CV. somatostatin receptors: Structure, function, ligands, and new nomenclature","volume":"70","author":"Tulipano","year":"2018","journal-title":"Pharmacol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/0024-3205(76)90263-0","article-title":"Differences in the degradation of hypothalamic releasing factors by rat and human serum","volume":"19","author":"Benuck","year":"1976","journal-title":"Life Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fendo.2012.00154","article-title":"Somatostatinergic systems: An update on brain functions in normal and pathological aging","volume":"3","author":"Martel","year":"2012","journal-title":"Front. Endocrinol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0005-2736(03)00235-9","article-title":"Somatostatin receptors","volume":"1616","author":"Stidsen","year":"2003","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00002018-199717050-00004","article-title":"A risk-benefit assessment of octreotide in the treatment of acromegaly","volume":"17","author":"Lamberts","year":"1997","journal-title":"Drug Saf."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: Will they fulfil old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","article-title":"Somatostatin and its receptor family","volume":"20","author":"Patel","year":"1999","journal-title":"Front. Neuroendocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","article-title":"Somatostatin and somatostatin receptor physiology","volume":"20","author":"Barnett","year":"2003","journal-title":"Endocrine"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pharmthera.2015.05.007","article-title":"Therapeutic uses of somatostatin and its analogues: Current view and potential applications","volume":"152","author":"Rai","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: Efficacy and mechanisms","volume":"15","author":"Shimon","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_12","unstructured":"(2019, December 22). Sandostatin\u00ae LAR Depot (Octreotide Acetate) for Injectable Suspension Dosing & Administration|HCP. Available online: https:\/\/www.hcp.novartis.com\/products\/sandostatin-lar-depot\/carcinoid-syndrome\/dosing-administration\/."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: Results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1073\/pnas.91.6.2315","article-title":"Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2","volume":"91","author":"Buscail","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00315353","article-title":"Pharmacokinetic study and effects on growth hormone secretion in healthy volunteers of the new somatostatin analogue BIM 23014","volume":"45","author":"Kuhn","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2125.1994.tb04344.x","article-title":"Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers","volume":"38","author":"Kuhn","year":"1994","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.12968\/hosp.2002.63.3.2062","article-title":"Somatuline Autogel: An extended release lanreotide formulation","volume":"63","author":"Lightman","year":"2002","journal-title":"Hosp. Med. Lond. Engl."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur. J. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.01876","article-title":"The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5","volume":"152","author":"Hofland","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0024-3205(94)00956-2","article-title":"Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors","volume":"56","author":"Panetta","year":"1995","journal-title":"Life Sci."},{"key":"ref_21","first-page":"724","article-title":"Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage","volume":"79","author":"Greenman","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","first-page":"1386","article-title":"Somatostatin receptor subtype gene expression in pituitary adenomas","volume":"80","author":"Miller","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_23","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure\u2019","volume":"152","author":"Nomikos","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/bs.pmbts.2015.11.002","article-title":"Neurosurgical treatment of acromegaly","volume":"138","author":"Buchfelder","year":"2016","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Endocrine Society Acromegaly: An endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1210\/jc.2004-1093","article-title":"Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly","volume":"90","author":"Bevan","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_30","first-page":"478","article-title":"Grupo Espa\u00f1ol del estudio OASIS [The OASIS study: Therapeutic management of acromegaly in standard clinical practice. Assessment of the efficacy of various treatment strategies]","volume":"58","author":"Gilabert","year":"2011","journal-title":"Endocrinol. Nutr. Organo Soc. Espanola Endocrinol. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11102-012-0384-x","article-title":"Changes in acromegaly treatment over four decades in spain: Analysis of the spanish acromegaly registry (REA)","volume":"16","author":"Sesmilo","year":"2013","journal-title":"Pituitary"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: A consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.endinu.2018.12.004","article-title":"ACROSTART: A retrospective study of the time to achieve hormonal control with lanreotide Autogel treatment in Spanish patients with acromegaly","volume":"66","author":"Resmini","year":"2019","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1530\/EJE-07-0488","article-title":"Preliminary data on biochemical remission of acromegaly after somatostatin analogs withdrawal","volume":"158","author":"Ronchi","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alvarez-Escola, C., and Cardenas-Salas, J. (2016). Active postoperative acromegaly: Sustained remission after discontinuation of somatostatin analogues. Endocrinol. Diabetes Metab. Case Rep., 2016.","DOI":"10.1530\/EDM-16-0092"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): A randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Gadelha, M., Bex, M., Colao, A., Pedroza Garc\u00eda, E.M., Poiana, C., Jimenez-Sanchez, M., Yener, S., Mukherjee, R., Bartalotta, A., and Maamari, R. (2020). Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front. Endocrinol., 10.","DOI":"10.3389\/fendo.2019.00931"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1210\/jc.2003-031052","article-title":"A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients","volume":"89","author":"Feelders","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","first-page":"140","article-title":"Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas","volume":"86","author":"Saveanu","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: Observations from 2090 acromegaly patients in acrostudy","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1530\/EJE-09-0322","article-title":"ACROSTUDY: The first 5 years","volume":"161","author":"Trainer","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Horm. IGF Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2016","journal-title":"Endocrine"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"5627","DOI":"10.1210\/jc.2005-0531","article-title":"Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist","volume":"90","author":"Frystyk","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000448429","article-title":"Somatostatin receptor expression in gh-secreting pituitary adenomas treated with long-acting somatostatin analogues in combination with pegvisomant","volume":"105","author":"Franck","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/147323001204000213","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/eje.0.1450137","article-title":"Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre","volume":"145","author":"Abe","year":"2001","journal-title":"Eur. J. Endocrinol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jcem.82.10.4283","article-title":"Effect of Octreotide Pretreatment on Surgical Outcome in Acromegaly","volume":"82","author":"Colao","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","first-page":"1","article-title":"Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: A systematic review and meta-analysis of comparative studies","volume":"9","author":"Yang","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/1043-2760(92)90041-X","article-title":"Glycoprotein hormone \u03b1-subunit in pituitary adenomas","volume":"3","author":"Persani","year":"1992","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/BF02739875","article-title":"Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas","volume":"6","author":"Ezzat","year":"1995","journal-title":"Endocr. Pathol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1530\/eje.0.1480433","article-title":"The changing spectrum of TSH-secreting pituitary adenomas: Diagnosis and management in 43 patients","volume":"148","author":"Socin","year":"2003","journal-title":"Eur. J. Endocrinol."},{"key":"ref_54","first-page":"610","article-title":"Thyrotropin-secreting pituitary tumors","volume":"17","author":"Persani","year":"1996","journal-title":"Endocr. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jcem.84.2.5505","article-title":"Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the national institutes of health","volume":"84","author":"Oldfield","year":"1999","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jcem.86.6.7593","article-title":"Efficacy of the long-acting octreotide formulation (octreotide-lar) in patients with thyrotropin-secreting pituitary adenomas","volume":"86","author":"Caron","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-109-6-487","article-title":"Transsphenoidal microsurgery for Cushing disease. A report of 216 cases","volume":"109","author":"Mampalam","year":"1988","journal-title":"Ann. Intern. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-130-10-199905180-00015","article-title":"Long-term mortality after transsphenoidal surgery for cushing disease","volume":"130","author":"Swearingen","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2265.1993.tb00975.x","article-title":"Transsphenoidal resection in Cushing\u2019s disease: Undetectable serum cortisol as the definition of successfuI treatment","volume":"38","author":"Trainer","year":"1993","journal-title":"Clin. Endocrinol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1530\/JOE-16-0332","article-title":"Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro","volume":"231","author":"Gahete","year":"2016","journal-title":"J. Endocrinol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0026-0495(96)90091-8","article-title":"Is there a role for somatostatin and its analogs in Cushing\u2019s syndrome?","volume":"45","author":"Lamberts","year":"1996","journal-title":"Metabolism"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11102-005-1404-x","article-title":"The role of somatostatin analogs in Cushing\u2019s disease","volume":"7","author":"Lamberts","year":"2004","journal-title":"Pituitary"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","article-title":"Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: A Phase III extension study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin. Endocrinol."},{"key":"ref_65","first-page":"17","article-title":"A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of cushing\u2019s syndrome","volume":"78","author":"Lamberts","year":"1994","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1210\/JC.2015-1589","article-title":"ABC study group conventional and nuclear medicine imaging in ectopic cushing\u2019s syndrome: A systematic review","volume":"100","author":"Isidori","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-2002-36708","article-title":"Gonadotropinomas","volume":"20","author":"Chaidarun","year":"2002","journal-title":"Semin. Reprod. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.endinu.2017.05.009","article-title":"Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects","volume":"64","author":"Mercado","year":"2017","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1385\/ENDO:20:3:279","article-title":"Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas","volume":"20","author":"Colao","year":"2003","journal-title":"Endocrine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s11154-008-9107-z","article-title":"Medical therapy of pituitary adenomas: Effects on tumor shrinkage","volume":"10","author":"Colao","year":"2009","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/00006123-199710000-00005","article-title":"A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. French multicenter octreotide study group","volume":"41","author":"Warnet","year":"1997","journal-title":"Neurosurgery"},{"key":"ref_72","unstructured":"(2020, January 21). Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients with Clinically Non-Functioning Pituitary Adenoma\u2014Study Results\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT01283542."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1023\/A:1012965617685","article-title":"Endocrine inactive and gonadotroph adenomas: Diagnosis and management","volume":"54","author":"Losa","year":"2001","journal-title":"J. Neurooncol."},{"key":"ref_74","first-page":"19","article-title":"Multimodal treatment of non-functional recidivant hypophyseal adenomas. A case report and literature review","volume":"60","year":"2017","journal-title":"Rev. Fac. Med. UNAM"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1677\/ERC-08-0181","article-title":"Medical therapy for clinically non-functioning pituitary adenomas","volume":"15","author":"Colao","year":"2008","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1517\/14656566.2011.568478","article-title":"Therapy of aggressive pituitary tumors","volume":"12","author":"Colao","year":"2011","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000497746","article-title":"Epidemiology and management challenges in prolactinomas","volume":"109","author":"Vroonen","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11102-005-5085-2","article-title":"Pharmacologic resistance in prolactinoma patients","volume":"8","author":"Molitch","year":"2005","journal-title":"Pituitary"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1210\/er.2005-9998","article-title":"Advances in the treatment of prolactinomas","volume":"27","author":"Gillam","year":"2006","journal-title":"Endocr. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","article-title":"Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy","volume":"64","author":"Delgrange","year":"2006","journal-title":"Clin. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: Long-term efficacy of quinagolide and outcome of pregnancy","volume":"135","author":"Morange","year":"1996","journal-title":"Eur. J. Endocrinol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1530\/EJE-09-0012","article-title":"Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: A study in 122 patients","volume":"160","author":"Delgrange","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000495775","article-title":"Management of dopamine agonist-resistant prolactinoma","volume":"109","author":"Maiter","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Chanson, P., and Maiter, D. (2017). Prolactinoma. The Pituitary, ScienceDirect.","DOI":"10.1016\/B978-0-12-804169-7.00016-7"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.mce.2012.01.026","article-title":"Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro: Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion","volume":"355","author":"Cuny","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"10163","DOI":"10.1158\/0008-5472.CAN-08-1857","article-title":"Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas","volume":"68","author":"Acunzo","year":"2008","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"K21","DOI":"10.1530\/EJE-19-0279","article-title":"Excellent response to pasireotide therapy in an aggressive and dopamine-resistant prolactinoma","volume":"181","author":"Coopmans","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13256-015-0514-y","article-title":"Large cell neuroendocrine carcinoma of the lung presenting as pseudoachalasia: A case report","volume":"9","author":"Anaizi","year":"2015","journal-title":"J. Med. Case Rep."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s004280100494","article-title":"Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy","volume":"439","author":"Papotti","year":"2001","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/MPA.0000000000000700","article-title":"Association between somatostatin receptor expression and clinical outcomes in neuroendocrine tumors","volume":"45","author":"Qian","year":"2016","journal-title":"Pancreas"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0921-4410(03)21025-5","article-title":"Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment","volume":"21","author":"Janson","year":"2003","journal-title":"Cancer Chemother. Biol. Response Modif."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2036.2009.04174.x","article-title":"Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours","volume":"31","author":"Modlin","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"712","DOI":"10.6004\/jnccn.2009.0050","article-title":"NCCN clinical practice guidelines in oncology: Neuroendocrine tumors","volume":"7","author":"Clark","year":"2009","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: Efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies","volume":"152","author":"Vezzosi","year":"2005","journal-title":"Eur. J. Endocrinol."},{"key":"ref_95","first-page":"271","article-title":"Pasireotide for malignant insulinoma","volume":"15","author":"Tirosh","year":"2016","journal-title":"Horm. Athens Greece"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/BF01655110","article-title":"Use of octreotide acetate for control of symptoms in patients with islet cell tumors","volume":"17","author":"Maton","year":"1993","journal-title":"World J. Surg."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","article-title":"Treatment of type II gastric carcinoid tumors with somatostatin analogues","volume":"343","author":"Tomassetti","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5423","DOI":"10.3748\/wjg.v11.i35.5423","article-title":"Treatment of zollinger-ellison syndrome","volume":"11","author":"Tomassetti","year":"2005","journal-title":"World J. Gastroenterol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1097\/00042737-200306000-00020","article-title":"Gastric carcinoid type I tumour: New diagnostic and therapeutic method","volume":"15","author":"Prommegger","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1046\/j.1365-2036.2000.00738.x","article-title":"Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR","volume":"14","author":"Tomassetti","year":"2000","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","article-title":"The glucagonoma syndrome. Clinical and pathologic features in 21 patients","volume":"75","author":"Wermers","year":"1996","journal-title":"Medicine"},{"key":"ref_102","first-page":"308","article-title":"Treatment of metastatic glucagonoma to the liver: Case report and literature review","volume":"31","author":"Casadei","year":"1999","journal-title":"Ital. J. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s11605-007-0177-0","article-title":"Pancreatic VIPomas: Subject review and one institutional experience","volume":"12","author":"Ghaferi","year":"2008","journal-title":"J. Gastrointest. Surg. Off. J. Soc. Surg. Aliment. Tract"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/MPA.0b013e3181b2bc7c","article-title":"Diagnosis and treatment of pancreatic vasoactive intestinal peptide endocrine tumors","volume":"38","author":"Song","year":"2009","journal-title":"Pancreas"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s12020-009-9146-6","article-title":"VIPoma with expression of both VIP and VPAC1 receptors in a patient with WDHA syndrome","volume":"35","author":"Nakayama","year":"2009","journal-title":"Endocrine"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/gut.42.6.792","article-title":"Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours","volume":"42","author":"Angeletti","year":"1998","journal-title":"Gut"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the promid study group","volume":"27","author":"Rinke","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1530\/ERC-15-0490","article-title":"Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study","volume":"23","author":"Caplin","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.2147\/OTT.S128547","article-title":"Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors","volume":"10","author":"Yao","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/annonc\/mdj113","article-title":"Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma","volume":"17","author":"Panzuto","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MEG.0b013e328359d1a6","article-title":"Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors","volume":"25","author":"Palazzo","year":"2013","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/bjc.2016.349","article-title":"Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours","volume":"115","author":"Laskaratos","year":"2016","journal-title":"Br. J. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1200\/JCO.19.00980","article-title":"Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The getne-trasgu study","volume":"37","author":"Lamarca","year":"2019","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"dgz035","DOI":"10.1210\/clinem\/dgz035","article-title":"Non-conventional doses of somatostatin analogs in patients with progressing well differentiated neuroendocrine tumor","volume":"105","author":"Lamberti","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1575-0922(07)71513-9","article-title":"Diagnosis and characteristics of intestinal carcinoid tumors. Carcinoid syndrome","volume":"54","year":"2007","journal-title":"Endocrinol. Nutr."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/00002030-199112000-00012","article-title":"Efficacy of octreotide in the management of chronic diarrhoea in AIDS","volume":"5","author":"Romeu","year":"1991","journal-title":"AIDS Lond. Engl."},{"key":"ref_119","first-page":"526","article-title":"Therapeutic options for gastrointestinal carcinoids","volume":"4","author":"Modlin","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance","volume":"88","author":"Ducreux","year":"2000","journal-title":"Cancer"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000082875","article-title":"Rapid and sustained relief from the symptoms of carcinoid syndrome: Results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide","volume":"80","author":"Ruszniewski","year":"2004","journal-title":"Neuroendocrinology"},{"key":"ref_122","first-page":"1068","article-title":"ELECT Study Group * evaluation of lanreotide depot\/autogel efficacy and safety as a carcinoid syndrome treatment (elect): A randomized, double-blind, placebo-controlled trial","volume":"22","author":"Vinik","year":"2016","journal-title":"Endocr. Pract. Off. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol."},{"key":"ref_123","first-page":"552","article-title":"Patient-reported outcomes with lanreotide Autogel\/Depot for carcinoid syndrome: An international observational study","volume":"48","author":"Ruszniewski","year":"2016","journal-title":"Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2016.12.030","article-title":"Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: An expert statement","volume":"69","author":"Davar","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cen.12411","article-title":"Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours","volume":"80","author":"Ramundo","year":"2014","journal-title":"Clin. Endocrinol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1210\/clinem\/dgz007","article-title":"Lanreotide therapy vs. active surveillance in men1-related pancreatic neuroendocrine tumors <2 cm","volume":"105","author":"Faggiano","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2","DOI":"10.4172\/2157-7412.1000179","article-title":"Combined biological therapy is effective to control all neuroendocrine tumor manifestations in a patient with men1 syndrome","volume":"4","author":"Marciello","year":"2013","journal-title":"J. Genet. Syndr. Gene Ther."},{"key":"ref_131","first-page":"2","article-title":"Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy","volume":"69","author":"Hussain","year":"2008","journal-title":"Horm. Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"F98","DOI":"10.1136\/fn.82.2.F98","article-title":"Practical management of hyperinsulinism in infancy","volume":"82","author":"Hussain","year":"2000","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_133","first-page":"69","article-title":"Congenital hyperinsulinism: Diagnosis and treatment update","volume":"9","author":"Demirbilek","year":"2017","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"key":"ref_134","first-page":"518","article-title":"Somatostatin in diabetic retinopathy","volume":"1","author":"Croxen","year":"2004","journal-title":"Pediatr. Endocrinol. Rev. PER"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2174\/157339906775473671","article-title":"Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy","volume":"2","author":"Carrasco","year":"2006","journal-title":"Curr. Diabetes Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.2337\/diacare.25.12.2282","article-title":"Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: Possible role in the development of proliferative diabetic retinopathy","volume":"25","author":"Lecube","year":"2002","journal-title":"Diabetes Care"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12020-018-1561-0","article-title":"Somatostatin and diabetic retinopathy: An evolving story","volume":"60","year":"2018","journal-title":"Endocrine"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000180771","article-title":"Suppression of growth hormone and somatomedin C by long-acting somatostatin analog SMS 201-995 in type I diabetes mellitus","volume":"27","author":"Plewe","year":"1987","journal-title":"Horm. Res."},{"key":"ref_139","first-page":"187","article-title":"Continuous subcutaneous octreotide infusion markedly suppresses IGF-I levels whilst only partially suppressing GH secretion in diabetics with retinopathy","volume":"120","author":"Hyer","year":"1989","journal-title":"Acta Endocrinol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000098503","article-title":"Use of long-acting somatostatin analogue treatment in diabetic retinopathy","volume":"39","author":"Boehm","year":"2007","journal-title":"Dev. Ophthalmol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2337\/diacare.23.4.504","article-title":"The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: A randomized controlled study","volume":"23","author":"Grant","year":"2000","journal-title":"Diabetes Care"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00003072-199503000-00010","article-title":"Somatostatin receptors in the orbits","volume":"20","author":"Durak","year":"1995","journal-title":"Clin. Nucl. Med."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/j.1365-2265.1995.tb02682.x","article-title":"Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease","volume":"42","author":"Krassas","year":"1995","journal-title":"Clin. Endocrinol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1089\/thy.1999.9.47","article-title":"Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease","volume":"9","author":"Krassas","year":"1999","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/bmj.304.6820.158","article-title":"Octreotide and Graves\u2019 ophthalmopathy and pretibial myxoedema","volume":"304","author":"Chang","year":"1992","journal-title":"BMJ"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1136\/bmj.304.6839.1444","article-title":"Octreotide and urinary glycosaminoglycan in Graves\u2019 disease","volume":"304","author":"Chang","year":"1992","journal-title":"BMJ"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/thy.1996.6.381","article-title":"The effect of somatostatin versus corticosteroid in the treatment of Graves\u2019 ophthalmopathy","volume":"6","author":"Kung","year":"1996","journal-title":"Thyroid Off. J. Am. Thyroid Assoc."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1530\/eje.0.1360416","article-title":"Lanreotide in the treatment of patients with thyroid eye disease","volume":"136","author":"Krassas","year":"1997","journal-title":"Eur. J. Endocrinol."},{"key":"ref_150","first-page":"517","article-title":"Dumping syndrome: Pathophysiology and treatment","volume":"20","author":"Ukleja","year":"2005","journal-title":"Nutr. Clin. Pract. Off. Publ. Am. Soc. Parenter. Enter. Nutr."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1001\/archsurg.1991.01410340073010","article-title":"Control of dumping symptoms by somatostatin analogue in patients after gastric surgery","volume":"126","author":"Gray","year":"1991","journal-title":"Arch. Surg."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1136\/pmj.77.909.441","article-title":"Therapeutic value of octreotide for patients with severe dumping syndrome\u2014A review of randomised controlled trials","volume":"77","author":"Irving","year":"2001","journal-title":"Postgrad. Med. J."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1507\/endocrj.EJ12-0288","article-title":"Octreotide improves early dumping syndrome potentially through incretins: A case report","volume":"60","author":"Sato","year":"2013","journal-title":"Endocr. J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1136\/bmj.290.6472.886","article-title":"Somatostatin and the dumping syndrome","volume":"290","author":"Long","year":"1985","journal-title":"Br. Med. J."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000201413","article-title":"The place of octreotide in the medical management of the dumping syndrome","volume":"57","author":"Scarpignato","year":"1996","journal-title":"Digestion"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00000658-199012000-00005","article-title":"Efficacy of octreotide acetate in treatment of severe postgastrectomy dumping syndrome","volume":"212","author":"Geer","year":"1990","journal-title":"Ann. Surg."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/j.1365-2036.2005.02681.x","article-title":"Efficacy of depot long-acting release octreotide therapy in severe dumping syndrome","volume":"22","author":"Penning","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1111\/apt.14664","article-title":"Safety and efficacy of pasireotide in dumping syndrome-results from a phase 2, multicentre study","volume":"47","author":"Tack","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00075197-200405000-00011","article-title":"Surgical management of high output enterocutaneous fistulae: A 24-year experience","volume":"7","author":"Haffejee","year":"2004","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_160","first-page":"237","article-title":"Role of somatostatin analogues in the management of enterocutaneous fistulae","volume":"14","author":"Jamil","year":"2004","journal-title":"J. Coll. Phys. Surg. Pak. Jcpsp"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000201075","article-title":"Treatment of gastrointestinal fistulas with sandostatin","volume":"54","author":"Guirao","year":"1993","journal-title":"Digestion"},{"key":"ref_162","first-page":"672","article-title":"Blind evaluation of the effect of octreotide (SMS 201-995), a somatostatin analogue, on small-bowel fistula output","volume":"2","author":"Sancho","year":"1987","journal-title":"Lancet Lond. Engl."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1155\/2004\/901570","article-title":"Somatostatin versus octreotide in the treatment of patients with gastrointestinal and pancreatic fistulas","volume":"18","author":"Leandros","year":"2004","journal-title":"Can. J. Gastroenterol. J. Can. Gastroenterol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/gast.2001.22529","article-title":"Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats","volume":"120","author":"Wiest","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/0016-5085(95)90590-1","article-title":"A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage","volume":"109","author":"Imperiale","year":"1995","journal-title":"Gastroenterology"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1055\/s-2007-1007133","article-title":"Pharmacological treatment of portal hypertension: An evidence-based approach","volume":"19","author":"Pagliaro","year":"1999","journal-title":"Semin. Liver Dis."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1053\/gast.2001.22451","article-title":"Octreotide for acute esophageal variceal bleeding: A meta-analysis","volume":"120","author":"Corley","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"e13437","DOI":"10.1097\/MD.0000000000013437","article-title":"Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials","volume":"97","author":"Zhou","year":"2018","journal-title":"Medicine"},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s12072-014-9594-9","article-title":"Efficacy of vasopressin\/terlipressin and somatostatin\/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: A systematic review and meta-analysis","volume":"9","author":"Wang","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/j.1523-1755.2004.00945.x","article-title":"Cyclic AMP, at the hub of the cystic cycle","volume":"66","author":"Torres","year":"2004","journal-title":"Kidney Int."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1046\/j.1365-2036.2001.01114.x","article-title":"Systematic review: The use of somatostatin or octreotide in refractory diarrhoea","volume":"15","author":"Szilagyi","year":"2001","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_173","first-page":"240","article-title":"Octreotide for medullary thyroid carcinoma associated diarrhoea","volume":"40","author":"Smid","year":"1992","journal-title":"Neth. J. Med."},{"key":"ref_174","first-page":"471","article-title":"A review of the use of somatostatin analogs in oncology","volume":"6","author":"Keskin","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/onc.2011.389","article-title":"The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells","volume":"31","author":"Gahete","year":"2012","journal-title":"Oncogene"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.mce.2008.01.006","article-title":"Biology of somatostatin in breast cancer","volume":"286","author":"Watt","year":"2008","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_177","first-page":"2646","article-title":"Treatment of R-3327 prostate tumors with a somatostatin analogue (somatuline) as adjuvant therapy following surgical castration","volume":"50","author":"Bogden","year":"1990","journal-title":"Cancer Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF00685857","article-title":"Phase I\u2013II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer","volume":"36","author":"Maulard","year":"1995","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14656560802694689","article-title":"Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)","volume":"10","author":"Mitsogiannis","year":"2009","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/bjp.2008.268","article-title":"Somatostatin inhibits colon cancer cell growth through cyclooxygenase-2 downregulation","volume":"155","author":"Colucci","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1046\/j.1365-2362.2001.00870.x","article-title":"CCK-B\/gastrin receptors in human colorectal cancer","volume":"31","author":"Schmitz","year":"2001","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1159\/000049163","article-title":"Somatostatin, its receptors and analogs, in lung cancer","volume":"47","author":"Schally","year":"2001","journal-title":"Chemotherapy"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.1991.330","article-title":"Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer","volume":"64","author":"Macaulay","year":"1991","journal-title":"Br. J. Cancer"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.lungcan.2011.09.014","article-title":"Long acting somatostatin analogues in combination to antineoplastic agents in the treatment of small cell lung cancer patients","volume":"76","author":"Zarogoulidis","year":"2012","journal-title":"Lung Cancer Amst. Neth."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1210\/jc.2008-1712","article-title":"Effects of somatostatin analogs on a growth hormone-releasing hormone secreting bronchial carcinoid, in vivo and in vitro studies","volume":"94","author":"Hofland","year":"2009","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000049167","article-title":"Octreotide for cancer of the liver and biliary tree","volume":"47","author":"Kouroumalis","year":"2001","journal-title":"Chemotherapy"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/hep.21468","article-title":"Long-acting octreotide versus placebo for treatment of advanced HCC: A randomized controlled double-blind study","volume":"45","author":"Becker","year":"2007","journal-title":"Hepatol. Baltim. Md"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Kvols","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1517\/14740338.2015.1059817","article-title":"Adverse events associated with somatostatin analogs in acromegaly","volume":"14","author":"Grasso","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_190","first-page":"754","article-title":"Long-acting somatostatin analogue therapy in obscure-overt gastrointestinal bleeding in noncirrhotic portal hypertension: A case report and literature review","volume":"22","author":"Hutchinson","year":"2010","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/ccr3.388","article-title":"Severe scalp hair loss in a female patient with acromegaly treated with lanreotide autogel after unsuccessful surgery","volume":"3","author":"Pelegrina","year":"2015","journal-title":"Clin. Case Rep."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","article-title":"The safety of available treatments options for neuroendocrine tumors","volume":"16","author":"Faggiano","year":"2017","journal-title":"Expert Opin. Drug Saf."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/5\/1682\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:02:52Z","timestamp":1760173372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/5\/1682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,29]]},"references-count":192,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["ijms21051682"],"URL":"https:\/\/doi.org\/10.3390\/ijms21051682","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,29]]}}}